XENETIC BIOSCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Basic
XENETIC BIOSCIENCES, INC. (XBIO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$10.89 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-03-16
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$1.20M.
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$7.56M.
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-06-30 was -$953.64K.
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was -$1.18M.
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$10.89M.
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$18.06M.
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$7.30M.
- XENETIC BIOSCIENCES, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$3.60M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$8.76M derived: sum of 2 quarters · filed 2021-03-16 | -$9.71M derived: sum of 3 quarters · filed 2021-03-16 | -$10.89M 10-K · filed 2021-03-16 |
| 2020-09-30 | -$7.56M 10-Q · filed 2020-11-12 | -$8.51M derived: sum of 2 quarters · filed 2020-11-12 | -$9.69M 10-Q · filed 2020-11-12 | -$10.86M derived: sum of 4 quarters · filed 2021-03-16 |
| 2020-06-30 | -$953.64K 10-Q · filed 2020-08-12 | -$2.13M 10-Q · filed 2020-08-12 | -$3.30M derived: sum of 3 quarters · filed 2021-03-16 | -$13.61M derived: sum of 4 quarters · filed 2021-03-16 |
| 2020-03-31 | -$1.18M 10-Q · filed 2020-05-14 | -$2.35M derived: sum of 2 quarters · filed 2021-03-16 | -$12.65M derived: sum of 3 quarters · filed 2021-03-16 | -$14.03M derived: sum of 4 quarters · filed 2021-03-16 |
| 2019-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$11.48M derived: sum of 2 quarters · filed 2021-03-16 | -$12.85M derived: sum of 3 quarters · filed 2021-03-16 | -$18.06M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$10.31M 10-Q · filed 2020-11-12 | -$11.68M derived: sum of 2 quarters · filed 2020-11-12 | -$16.89M 10-Q · filed 2020-11-12 | -$18.53M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$1.38M 10-Q · filed 2020-08-12 | -$6.58M 10-Q · filed 2020-08-12 | -$8.22M derived: sum of 3 quarters · filed 2020-08-12 | -$10.04M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | -$5.21M 10-Q · filed 2020-05-14 | -$6.85M derived: sum of 2 quarters · filed 2020-05-14 | -$8.66M derived: sum of 3 quarters · filed 2020-05-14 | -$10.68M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$3.45M derived: sum of 2 quarters · filed 2020-03-26 | -$5.48M derived: sum of 3 quarters · filed 2020-03-26 | -$7.30M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$1.81M 10-Q · filed 2019-11-14 | -$3.84M derived: sum of 2 quarters · filed 2019-11-14 | -$5.66M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$2.03M 10-Q · filed 2019-08-14 | -$3.85M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$1.82M 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | -$3.60M 10-K · filed 2018-03-30 | |||
| 2016-12-31 | -$58.24M 10-K · filed 2018-03-30 | |||
| 2015-12-31 | -$12.51M 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |